![]() J Palliat Care 1996, 12:21–30.īurke AL, Diamond PL, Hulbert J, et al.: Terminal restlessness: its management and the role of midazolam. Palliat Med 1992, 6:293–298.īillings JA, Block SD: Slow euthanasia. South Med J 1991, 84:332–337.īack IN: Terminal restlessness in patients with advanced malignant disease. Greene WR, Davis WH: Titrated intravenous barbiturates in the control of symptoms in patients with terminal cancer. J Pain Symptom Manage 1995, 10:131–141.Įnck RE: Drug induced terminal sedation for symptom control. ![]() J Pain Symptom Manage 1994, 9:298–302.īreitbart W, Bruera E, Chochinov H, et al.: Neuropsychiatric syndromes and psychological symptoms in patients with advanced cancer. J Palliat Care 1993, 9:4–8.įainsinger RL, MacEachern T, Miller MJ, et al.: The use of hypodermoclysis for rehydration in terminally ill cancer patients. J Neurol 1997, 244( suppl 14):S2-S10.įainsinger RL, Tapper M, Bruera E: A perspective on the management of delirium in terminally ill patients on a palliative care unit. Voltz R, Borasio GD: Palliative therapy in the terminal stage of neurological disease. J Pain Symptom Manage 1990, 5:83–93.įainsinger R, Miller MJ, Bruera E, et al.: Symptom control during the last week of life on a palliative care unit. J Palliat Care 1990, 6:7–11.Ĭoyle N, Adelhardt J, Foley KM, Portenoy RK: Character of terminal illness in the advanced cancer patient: pain and other symptoms during the last four weeks of life. Ventafridda V, Ripamonte C, De Conno F, et al.: Symptom prevalence and control during cancer patients’ last days of life. McKegney FP, Bailey LR, Yates JW: Prediction and management of pain patients with advanced cancer. Grond S, Zech D, Schug SA, et al.: Validation of World Health Organization guidelines for cancer pain relief during the last days and hours of life. Lichter I, Hunt E: The last 48 hours of life. Midazolam is reported to be the most frequently used agent.Īdam J: ABC of palliative care: the last 48 hours. This study includes a diverse international population and characterizes the symptoms requiring palliative sedation, with delirium and dyspnea being most common. Ann Int Med 2000, 132:408–414.įainsinger RL, Waller A, Bercovici M, et al.: A multicentre international study of sedation for uncontrolled symptoms in terminally ill patients. Quill TE, Byock IR: Responding to intractable terminal suffering: the role of sedation and voluntary refusal of food and fluids. Wallston KA, Burger C, Smith RA, Baugher RJ: Comparing the quality of death for hospice and non-hospice cancer patients. Seale CF: What happens in hospices: a review of research evidence. At that time, a maintenance dose should be prescribed. ![]() This author emphasizes that sedative titration should be focused on clinical need and not on level of sedation and recommends that the physician be at the bedside to titrate medication until the patient’s symptoms are controlled. Wein S: Sedation in the imminently dying patient. Singer PA, Martin DK, Kelner M: Quality end of life care: patients’ perspectives.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |